Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters

Hideo Otsuki, Toru Kimura, Takashi Yamaga, Takeo Kosaka, Jun ichi Suehiro, Hiroyuki Sakurai

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND: Leucine stimulates cancer cell proliferation through the mTOR pathway, therefore, inhibiting leucine transporters may be a novel therapeutic target for cancer. L-type amino acid transporter (LAT) 1, a Na+-independent amino acid transporter, is highly expressed in many tumor cells. However, leucine transporter(s) in different stages of prostate cancer, particularly in the stages of castration resistance with androgen receptor (AR) expression, is unclear. METHODS: LNCaP and DU145 and PC-3 cell lines were used as a model of androgen dependent, and metastatic prostate cancer. A new "LN-cr" cell line was established after culturing LNCaP cells for 6 months under androgen-free conditions, which is considered a model of castration resistant prostate cancer (CRPC) with androgen AR expression. The expression of leucine transporters was investigated with quantitative PCR and immunofluorescence. Uptake of 14C Leucine was examined in the presence or absence of BCH (a pan-LAT inhibitor), JPH203 (an LAT1-specific inhibitor), or Na+. Cell growth was assessed with MTT assay. siRNA studies were performed to evaluate the indispensability of y+LAT2 on leucine uptake and cell viability in LN-cr. RESULTS: Cell viability showed a 90% decrease in the absence of leucine in all four cell lines. LNCaP cells principally expressed LAT3, and their leucine uptake was more than 90% Na+-independent. BCH, but not JPH203, inhibited leucine uptake, and cell proliferation (IC50BCH:15mM). DU145 and PC-3 cells predominantly expressed LAT1. Leucine uptake and cell growth were suppressed by BCH or JPH203 in a dose-dependent manner (IC50BCH: ∼20mM, IC50JPH203: ∼5μM). In LN-cr cells, Na+-dependent uptake of leucine was 3.8pmol/mgprotein/min, while, Na+-independent uptake was only 0.52 (P<0.05). Leucine uptake of LN-cr was largely (∼85%) Na+-dependent. y+LAT2 expression was confirmed in LN-cr. Knockdown of y+LAT2 lead to significant leucine uptake inhibition (40%) and cell growth inhibition (20%). CONCLUSIONS: New CRPC cell line with increased expression of y+LAT2 as a leucine transporter was established in vitro. Anti-leucine transporter therapy could be an important option against prostate cancer. Prostate

Original languageEnglish
JournalProstate
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Androgen Receptors
Leucine
Prostatic Neoplasms
Amino Acid Transport Systems
Castration
Androgens
Cell Line
Cell Survival
Growth
Cell Proliferation
Neoplasms
Small Interfering RNA
Fluorescent Antibody Technique
Prostate

Keywords

  • JPH203
  • LAT
  • Leucine
  • Prostate cancer
  • Transporter

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters. / Otsuki, Hideo; Kimura, Toru; Yamaga, Takashi; Kosaka, Takeo; Suehiro, Jun ichi; Sakurai, Hiroyuki.

In: Prostate, 2016.

Research output: Contribution to journalArticle

Otsuki, Hideo ; Kimura, Toru ; Yamaga, Takashi ; Kosaka, Takeo ; Suehiro, Jun ichi ; Sakurai, Hiroyuki. / Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters. In: Prostate. 2016.
@article{49519363566e43d69fbddd57b53a11a2,
title = "Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters",
abstract = "BACKGROUND: Leucine stimulates cancer cell proliferation through the mTOR pathway, therefore, inhibiting leucine transporters may be a novel therapeutic target for cancer. L-type amino acid transporter (LAT) 1, a Na+-independent amino acid transporter, is highly expressed in many tumor cells. However, leucine transporter(s) in different stages of prostate cancer, particularly in the stages of castration resistance with androgen receptor (AR) expression, is unclear. METHODS: LNCaP and DU145 and PC-3 cell lines were used as a model of androgen dependent, and metastatic prostate cancer. A new {"}LN-cr{"} cell line was established after culturing LNCaP cells for 6 months under androgen-free conditions, which is considered a model of castration resistant prostate cancer (CRPC) with androgen AR expression. The expression of leucine transporters was investigated with quantitative PCR and immunofluorescence. Uptake of 14C Leucine was examined in the presence or absence of BCH (a pan-LAT inhibitor), JPH203 (an LAT1-specific inhibitor), or Na+. Cell growth was assessed with MTT assay. siRNA studies were performed to evaluate the indispensability of y+LAT2 on leucine uptake and cell viability in LN-cr. RESULTS: Cell viability showed a 90{\%} decrease in the absence of leucine in all four cell lines. LNCaP cells principally expressed LAT3, and their leucine uptake was more than 90{\%} Na+-independent. BCH, but not JPH203, inhibited leucine uptake, and cell proliferation (IC50BCH:15mM). DU145 and PC-3 cells predominantly expressed LAT1. Leucine uptake and cell growth were suppressed by BCH or JPH203 in a dose-dependent manner (IC50BCH: ∼20mM, IC50JPH203: ∼5μM). In LN-cr cells, Na+-dependent uptake of leucine was 3.8pmol/mgprotein/min, while, Na+-independent uptake was only 0.52 (P<0.05). Leucine uptake of LN-cr was largely (∼85{\%}) Na+-dependent. y+LAT2 expression was confirmed in LN-cr. Knockdown of y+LAT2 lead to significant leucine uptake inhibition (40{\%}) and cell growth inhibition (20{\%}). CONCLUSIONS: New CRPC cell line with increased expression of y+LAT2 as a leucine transporter was established in vitro. Anti-leucine transporter therapy could be an important option against prostate cancer. Prostate",
keywords = "JPH203, LAT, Leucine, Prostate cancer, Transporter",
author = "Hideo Otsuki and Toru Kimura and Takashi Yamaga and Takeo Kosaka and Suehiro, {Jun ichi} and Hiroyuki Sakurai",
year = "2016",
doi = "10.1002/pros.23263",
language = "English",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters

AU - Otsuki, Hideo

AU - Kimura, Toru

AU - Yamaga, Takashi

AU - Kosaka, Takeo

AU - Suehiro, Jun ichi

AU - Sakurai, Hiroyuki

PY - 2016

Y1 - 2016

N2 - BACKGROUND: Leucine stimulates cancer cell proliferation through the mTOR pathway, therefore, inhibiting leucine transporters may be a novel therapeutic target for cancer. L-type amino acid transporter (LAT) 1, a Na+-independent amino acid transporter, is highly expressed in many tumor cells. However, leucine transporter(s) in different stages of prostate cancer, particularly in the stages of castration resistance with androgen receptor (AR) expression, is unclear. METHODS: LNCaP and DU145 and PC-3 cell lines were used as a model of androgen dependent, and metastatic prostate cancer. A new "LN-cr" cell line was established after culturing LNCaP cells for 6 months under androgen-free conditions, which is considered a model of castration resistant prostate cancer (CRPC) with androgen AR expression. The expression of leucine transporters was investigated with quantitative PCR and immunofluorescence. Uptake of 14C Leucine was examined in the presence or absence of BCH (a pan-LAT inhibitor), JPH203 (an LAT1-specific inhibitor), or Na+. Cell growth was assessed with MTT assay. siRNA studies were performed to evaluate the indispensability of y+LAT2 on leucine uptake and cell viability in LN-cr. RESULTS: Cell viability showed a 90% decrease in the absence of leucine in all four cell lines. LNCaP cells principally expressed LAT3, and their leucine uptake was more than 90% Na+-independent. BCH, but not JPH203, inhibited leucine uptake, and cell proliferation (IC50BCH:15mM). DU145 and PC-3 cells predominantly expressed LAT1. Leucine uptake and cell growth were suppressed by BCH or JPH203 in a dose-dependent manner (IC50BCH: ∼20mM, IC50JPH203: ∼5μM). In LN-cr cells, Na+-dependent uptake of leucine was 3.8pmol/mgprotein/min, while, Na+-independent uptake was only 0.52 (P<0.05). Leucine uptake of LN-cr was largely (∼85%) Na+-dependent. y+LAT2 expression was confirmed in LN-cr. Knockdown of y+LAT2 lead to significant leucine uptake inhibition (40%) and cell growth inhibition (20%). CONCLUSIONS: New CRPC cell line with increased expression of y+LAT2 as a leucine transporter was established in vitro. Anti-leucine transporter therapy could be an important option against prostate cancer. Prostate

AB - BACKGROUND: Leucine stimulates cancer cell proliferation through the mTOR pathway, therefore, inhibiting leucine transporters may be a novel therapeutic target for cancer. L-type amino acid transporter (LAT) 1, a Na+-independent amino acid transporter, is highly expressed in many tumor cells. However, leucine transporter(s) in different stages of prostate cancer, particularly in the stages of castration resistance with androgen receptor (AR) expression, is unclear. METHODS: LNCaP and DU145 and PC-3 cell lines were used as a model of androgen dependent, and metastatic prostate cancer. A new "LN-cr" cell line was established after culturing LNCaP cells for 6 months under androgen-free conditions, which is considered a model of castration resistant prostate cancer (CRPC) with androgen AR expression. The expression of leucine transporters was investigated with quantitative PCR and immunofluorescence. Uptake of 14C Leucine was examined in the presence or absence of BCH (a pan-LAT inhibitor), JPH203 (an LAT1-specific inhibitor), or Na+. Cell growth was assessed with MTT assay. siRNA studies were performed to evaluate the indispensability of y+LAT2 on leucine uptake and cell viability in LN-cr. RESULTS: Cell viability showed a 90% decrease in the absence of leucine in all four cell lines. LNCaP cells principally expressed LAT3, and their leucine uptake was more than 90% Na+-independent. BCH, but not JPH203, inhibited leucine uptake, and cell proliferation (IC50BCH:15mM). DU145 and PC-3 cells predominantly expressed LAT1. Leucine uptake and cell growth were suppressed by BCH or JPH203 in a dose-dependent manner (IC50BCH: ∼20mM, IC50JPH203: ∼5μM). In LN-cr cells, Na+-dependent uptake of leucine was 3.8pmol/mgprotein/min, while, Na+-independent uptake was only 0.52 (P<0.05). Leucine uptake of LN-cr was largely (∼85%) Na+-dependent. y+LAT2 expression was confirmed in LN-cr. Knockdown of y+LAT2 lead to significant leucine uptake inhibition (40%) and cell growth inhibition (20%). CONCLUSIONS: New CRPC cell line with increased expression of y+LAT2 as a leucine transporter was established in vitro. Anti-leucine transporter therapy could be an important option against prostate cancer. Prostate

KW - JPH203

KW - LAT

KW - Leucine

KW - Prostate cancer

KW - Transporter

UR - http://www.scopus.com/inward/record.url?scp=84990233880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990233880&partnerID=8YFLogxK

U2 - 10.1002/pros.23263

DO - 10.1002/pros.23263

M3 - Article

C2 - 27696482

AN - SCOPUS:84990233880

JO - Prostate

JF - Prostate

SN - 0270-4137

ER -